Results 121 to 130 of about 8,676,773 (167)
Some of the next articles are maybe not open access.
SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia.
Caroleen Drachenberg +11 more
openaire +1 more source
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia.
Caroleen Drachenberg +11 more
openaire +1 more source
SLEEPJ
Abstract Introduction In the US, low-sodium oxybate (LXB; Xywav®) is approved by the Food and Drug Administration for the treatment of idiopathic hypersomnia (IH) in adults, and has the option for individualized dosing. The LYRICAL study examined the real-world treatment experience of US adults
Caroleen Drachenberg +10 more
openaire +1 more source
Abstract Introduction In the US, low-sodium oxybate (LXB; Xywav®) is approved by the Food and Drug Administration for the treatment of idiopathic hypersomnia (IH) in adults, and has the option for individualized dosing. The LYRICAL study examined the real-world treatment experience of US adults
Caroleen Drachenberg +10 more
openaire +1 more source
SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
R Sangal +8 more
openaire +1 more source
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
R Sangal +8 more
openaire +1 more source
SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Alyssa Cairns +8 more
openaire +1 more source
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Alyssa Cairns +8 more
openaire +1 more source
SLEEP
Abstract Introduction Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on
David Plante +10 more
openaire +1 more source
Abstract Introduction Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on
David Plante +10 more
openaire +1 more source
SLEEPJ
Abstract Introduction People with idiopathic hypersomnia often experience sleep inertia, characterized by profound difficulty waking up with grogginess, disorientation, and cognitive impairment immediately after awakening.
Deborah Nichols +8 more
openaire +1 more source
Abstract Introduction People with idiopathic hypersomnia often experience sleep inertia, characterized by profound difficulty waking up with grogginess, disorientation, and cognitive impairment immediately after awakening.
Deborah Nichols +8 more
openaire +1 more source
SLEEP
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Richard Bogan +8 more
openaire +1 more source
Abstract Introduction Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB, Xywav®) treatment on outcomes ...
Richard Bogan +8 more
openaire +1 more source
SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia (IH).
Caroleen Drachenberg +11 more
openaire +1 more source
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia (IH).
Caroleen Drachenberg +11 more
openaire +1 more source
SLEEP
Abstract Introduction High sodium intake can increase blood pressure (BP) and future cardiovascular risk. Individuals with narcolepsy have an elevated cardiovascular comorbidity burden before considering medication-specific risks.
William White +5 more
openaire +1 more source
Abstract Introduction High sodium intake can increase blood pressure (BP) and future cardiovascular risk. Individuals with narcolepsy have an elevated cardiovascular comorbidity burden before considering medication-specific risks.
William White +5 more
openaire +1 more source
SLEEP
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. To examine the long-term safety of LXB in this population, this post hoc analysis evaluated treatment-emergent adverse events (TEAEs) over ...
Richard Bogan +4 more
openaire +1 more source
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. To examine the long-term safety of LXB in this population, this post hoc analysis evaluated treatment-emergent adverse events (TEAEs) over ...
Richard Bogan +4 more
openaire +1 more source